References
  1. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer . 2002;38(13):1677-1684
  2. Kaestner SA, Sewell GJ. Chemotherapy dosing part I: scientific basis for current practice and use of body surface area. Clin Oncol (R Coll Radiol). 2007;19(1):23-37.
  3. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res. 1958;18(7):853-856.
  4. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs.2001;19(2):171-177.
  5. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.J Natl Cancer Inst. 2002;94(24):1883-1888.
  6. Engels FK, Loos WJ, van der Bol JM, et al. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res. 2011;17(2): 353-362.
  7. Prado CMM, Baracos VE, McCargar LJ, et al. Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity. Clin Cancer Res. 2007;13(11):3264-3268.
  8. Gibbs JP, Gooley T, Corneau B, et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood.1999;93(12):4436-4440.
  9. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel.Clin Pharmacokinet. 1999;36(2):99-114.
  10. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res.1996;56(6):1296-1302.
  11. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res. 2000;6(7):2598-2603.
  12. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel : recent developments. Clin Pharmacokinet.2006;45(3):235-252.
  13. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998;16(1):187-196.
  14. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet.1994;26(4):292-307.
  15. Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R. Relationships between body composition parameters and fluorouracil pharmacokinetics.Br J Clin Pharmacol. 2002;54(2):131-139.
  16. Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007;25(30):4707-4713.
  17. Prado CM, Lima IS, Baracos VE, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol. 2011;67(1):93-101.
  18. Thompson PA, Rosner GL, Matthay KK, et al. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol.2009;64(2):243-251.
  19. Wong AL, Seng KY, Ong EM, et al. Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat.2014;144(1):143-152.
  20. Sjøblom B, Grønberg BH, Benth JŠ, et al. Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer. 2015;90(1):85-91.
  21. Sjøblom B, Benth JŠ, Grønberg BH, et al. Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017;18(2):e129-e136.
  22. Ali R, Baracos VE, Sawyer MB, et al. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med.2016;5(4):607-616.
  23. Cushen SJ, Power DG, Teo MY, et al. Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib. Am J Clin Oncol.2017;40(1):47-52.
  24. Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos. 1995;23(10):1110-1116.
  25. Nawaratne S, Brien JE, Seeman E, et al. Relationships among liver and kidney volumes, lean body mass and drug clearance. Br J Clin Pharmacol. 1998;46(5):447-452.
  26. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998;16(1):187-196.
  27. Baille P, Bruno R, Schellens JH, et al. Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res. 1997;3(9):1535-1538.
  28. Lin YS, Lockwood GF, Graham MA, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.Pharmacogenetics. 2001;11(9):781-791.
  29. European Medicines Agency (2009) EMEA/CHMP/EWP/192217/2009 - Guidance on Validation of Bioanalytical Methods. European Medicines Agency Committee for Medicinal Products for Human Use.
  30. CTCAE 4.03. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010).
  31. Schorr M, Dichtel LE, Gerweck AV, et al. Sex differences in body composition and association with cardiometabolic risk. Biol Sex Differ. 2018;9(1):28. Published 2018 Jun 27.
  32. Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.J Clin Oncol. 2021;39(18):2037-2048.
  33. de Vries Schultink AHM, Crombag MBS, van Werkhoven E, et al. Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort. Cancer Med. 2019;8(4):1406-1415.
  34. Bredella MA, Ghomi RH, Thomas BJ, et al. Comparison of DXA and CT in the assessment of body composition in premenopausal women with obesity and anorexia nervosa. Obesity (Silver Spring).2010;18(11):2227-2233.